DEEn Dictionary De - En
DeEs De - Es
DePt De - Pt
 Vocabulary trainer

Spec. subjects Grammar Abbreviations Random search Preferences
Search in Sprachauswahl
Search for:
Mini search box
 

4 similar results for Clive
Tip: Conversion of units

 German  English

Clive, D., Johnson, K. O., Spector, J. F. S., Batson, A. G. and Brown M. M. M. (1979), Validation and Characterisation of the L5178Y/TK+/- Mouse Lymphoma Mutagen Assay System, Mutat. [EU] Clive, D., Johnson, K.O., Spector, J.F.S., Batson, A.G. and Brown M.M.M., (1979) Validation and Characterisation of the L5178Y/TK+/- Mouse Lymphoma Mutagen Assay System. Mutat.

Clive, D., McCuen, R., Spector, J. F. S., Piper, C. and Mavournin, K. H. (198 3), Specific Gene Mutations in L5178Y Cells in Culture. [EU] Clive, D., McCuen, R., Spector, J.F.S., Piper, C. and Mavournin, K.H., (1983) Specific Gene Mutations in L5178Y Cells in Culture. A Report of the U.S. Environmental Protection Agency Gene-Tox Program.

Moore, M. M., Clive, D., Hozier, J. C., Howard, B. E., Batson, A. G., Turner, N. T. and Sawyer, J. (1985), Analysis of Trifluorothymidine-Resistant (TFT) and Mutants of L5178Y/TK Mouse Lymphoma Cells, Mutation Res.. 151, 161-174. [EU] Moore, M.M., Clive, D., Hozier, J.C., Howard, B.E., Batson, A.G., Turner, N.T. and Sawyer, J., (1985) Analysis of Trifluorothymidine-Resistant (TFTr) Mutants of L5178Y/TK+/- Mouse Lymphoma Cells. Mutation Res., 151, p. 161-174.

Turner, N. T., Batson, A. G. and Clive, D. (1984), Procedures for the L5178Y/TK+/- - TK+/- Mouse Lymphoma Cell Mutagenicity Assay, in: Kilbey, B. J. et al (eds.) [EU] Turner, N.T., Batson, A.G. and Clive, D., (1984) Procedures for the L5178Y/TK+/- - TK+/- Mouse Lymphoma Cell Mutagenicity Assay. In: Kilbey, B.J. et al (eds.)

The example sentences [G] were kindly provided by the Goethe Institute.
Sentences marked by [EU] derived from DGT Multilingual Translation Memory. The European Commission retains ownership of the copyright in the original data.
No guarantee of accuracy or completeness!
©TU Chemnitz, 2006-2024
Your feedback:
Ad partners